BioArctic develops new antibody treatment for ALS
Stockholm, November 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company’s development project ND3014. For the first time, ...
Press releases
New data on lecanemab presented at the CTAD Alzheimer conference
Stockholm, November 15, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai held several oral presentations at the 14[th] Clinical Trials on Alzheimer’s ...
DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer’s disease
Stockholm, November 8, 2021 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led ...
New data published on ABBV-0805 in Neurobiology of Disease
Stockholm, November 8, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has published an article in Neurobiology of Disease describing new preclinical data for the ...
New data on lecanemab to be presented at the 14[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference
Stockholm, November 4, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai today announced that they will hold several oral presentations revealing new ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET
Stockholm, Sweden, October 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Interim Report for the period January – September 2021 ...
New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease
Stockholm, September 10, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-?-synuclein antibody ABBV-0805 at the International ...
Eisai presented latest data from the lecanemab clinical program at AAIC 2021
Stockholm, July 30, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, ...
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)
Stockholm, July 21, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer’s Association International Conference (AAIC) to ...
BioArctic receives patent in Japan for new antibodies targeting Alzheimer’s disease
Stockholm, May 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) has allowed the company’s ...
Lecanemab (BAN2401) Phase 2b study in early Alzheimer’s disease published in peer-reviewed journal, Alzheimer’s Research & Therapy
Stockholm April 20, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b ...
Invitation to presentation of BioArctic’s Interim Report for the period January – March 2021 on April 21 at 9.30 a.m. CET
Stockholm, Sweden, April 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)
will publish the company’s Interim Report for the period January – March 2021 ...
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021
Stockholm, March 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the ...
Latest lecanemab data to be presented at the AD/PD™ congress
Stockholm, March 5, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...
Eisai increases the number of participants in Clarity AD study
Stockholm, February 3, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately ...
BioArctic receives European patent for new antibodies targeting Alzheimer’s disease
Stockholm, January 27, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant ...
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2020 on February 4 at 9.30 a.m. CET
Stockholm, Sweden, January 26, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for the period January – December ...
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
Stockholm, November 9, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the ...
BioArctic’s partner Eisai to present latest data on BAN2401 at CTAD conference
Stockholm, October 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will conduct four oral presentations related to ...
BioArctic winner of the Allbright Award 2020
Stockholm, October 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2020 on October 14 at 9.30 a.m. CET
Stockholm, Sweden, October 6, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2020 on Wednesday, ...
Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020
Stockholm, July 30, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai presented the latest data from the open-label ...
BioArctic’s partner Eisai to present update on the development of BAN2401 at Alzheimer’s Association International Conference 2020
Stockholm, July 22, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will present the study design of the ...
New global Phase 3 program of BAN2401 initiated in preclinical (asymptomatic) Alzheimer’s disease
Stockholm, July 14, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its business partner Eisai, in collaboration with Alzheimer’s Clinical Trials Consortium ...
BioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease
Stockholm, Sweden, June 29, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they ...
Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401
Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the ...
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2019 on February 6 at 9.30 a.m. CET
Stockholm, Sweden, January 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...
BioArctic strengthens its management team with two strategic recruitments
Stockholm, Sweden, December 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will be strengthening its management team in 2020 through two strategic recruitments. ...
BioArctic and Eisai to present data on BAN2401 at the Clinical Trials on Alzheimer’s Disease conference
Stockholm, Sweden, December 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the 12th ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2019 on October 24 at 9.30 a.m. CET
Stockholm, Sweden, October 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September ...
BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019
Stockholm, Sweden, July 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The ...
BioArctic’s co-founder received AAIC Lifetime Achievement Award
Professor Lars Lannfelt received prestigious international award for outstanding research in Alzheimer’s disease
BioArctic and Eisai to present BAN2401 at the Alzheimer’s Association International Conference 2019
Stockholm, Sweden, July 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at ...
Invitation to presentation of BioArctic’s Interim Report for the second quarter of 2019 on July 11 at 9.30 a.m. CET
Stockholm, Sweden, July 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2019 ...
BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment
Stockholm, Sweden, May 23, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. ...
BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease
Stockholm, Sweden, May 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer’s Clinical Trials Consortium (ACTC) and BioArctic’s partner ...
BioArctic’s Board of Directors and management increase their shareholdings
Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that nine members of the company's Board and management today have called ...
Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET
Stockholm, Sweden, April 29, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2019 ...
BioArctic receives grant from Vinnova for a collaborative research project to increase brain uptake of antibodies
Stockholm, Sweden, April 3, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 ...
BioArctic’s partner Eisai to give poster presentations on BAN2401 in early Alzheimer’s disease at the AD/PD conference in Lisbon
Stockholm, Sweden, March 25, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that its partner Eisai will give poster presentations related to BAN2401 in ...
Invitation to presentation of BioArctic’s Full Year Report 2018 on February 14, 2019
Stockholm, Sweden, February 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...
BioArctic employs Gunilla Andersson as Senior Director HR
Stockholm, Sweden, December 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Gunilla Andersson assumes the new position as Senior Director HR ...
BioArctic to present at Jefferies 2018 London Healthcare Conference on November 15
Stockholm, Sweden, November 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at ...
BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD
Stockholm, Sweden, October 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai will present additional data on the anti-amyloid (Aβ) ...
Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018
Stockholm, Sweden, August 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2018 ...
BioArctic receives this year’s SwedenBIO Award
Stockholm, Sweden, May 16, 2018 – BioArctic AB today received the SwedenBIO Award 2018. The prize is awarded to a company that has distinguished itself by ...
Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018
Stockholm, Sweden, April 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2018 ...
EXERCISE OF OVER-ALLOTMENT OPTION AND END OF THE STABILIZATION PERIOD
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
Invitation to presentation of BioArctic’s Interim Report January – September 2017 on November 8
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) publishes the company’s Interim Report for the period January – September 2017 on November 8, 2017 at 08:00 a.m. ...
Stabilization notice
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
Trading in BioArctic’s B-shares commences today on Nasdaq Stockholm
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
